Scientists discovered two microRNAs — tiny RNA molecules that control the activity of several genes — playing a key role in the development of Friedreich’s ataxia (FA) that may be promising candidates for its treatment. Their findings were reported in the study, “A Comprehensive Transcriptome…
RaNA Therapeutics, a Cambridge, Massachusetts-based biotech company that develops next-generation RNA-targeted medicines and which currently has a lead program in Friedreich’s Ataxia, announced that its CEO Ronald Renaud will present a corporate overview on Feb. 8 at the 18th annual BIO CEO & Investor Conference in New York City. RaNA’s management will also…
The National Ataxia Foundation (NAF), an organization dedicated to improving the lives of those affected by ataxia through support, education, and research, recently released a list of study proposals awarded funding for 2015. One of the awarded proposals, written by a post-doctoral candidate, Dr. Yu Miyazaki, M.D., Ph.D.
Get regular updates to your inbox.